Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors

US11319324B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Marcus Koppitz · Berlin, DE
• Holger Siebeneicher · Berlin, DE
• Nico Bräuer · Falkensee, DE
• Elisabeth Pook · Wuppertal, DE
• Andrea Rotgeri · Berlin, DE
• Roland Neuhaus · Berlin, DE
• Oliver Martin Fischer · Berlin, DE
• Jens Nagel · Daxweiler, DE
• Adam James Davenport · Abingdon, GB
• James Lindsay Carr · Cambridge, GB
• Robert James Townsend · Abingdon, GB
• Nina Connelly Ursinyova · Abingdon, GB
• Shelley Anne Parrott · Abingdon, GB

Key dates

• Filing date: Oct 18, 2018
• Grant date: May 3, 2022
• Expiry date: Oct 18, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P15/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.